ArticleEmerging microbes & infections2026
Differential pathogenesis and antiviral treatment outcomes of MPXV clade Ib and clade IIb in a BALB/c mouse model.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global emergence of monkeypox virus (MPXV) clade IIb since 2022, together with the recent spread of clade Ib, underscores the continuing public health threat posed by MPXV. Clinical and epidemiological observations suggest that clade Ib infection may differ from clade IIb infection, but the biological basis of these differences remains insufficiently defined. In this study, we established an intranasal BALB/c mouse model of MPXV clade Ib infection and compared its pathogenicity with that of clade IIb. Clade Ib caused lethal disease at an inoculation dose approximately ten-fold lower than that required for clade IIb. Compared with clade IIb, clade Ib infection showed faster disease progression, higher pulmonary viral burden at later stages of infection, and more severe lung pathology. Single-cell transcriptome and cytokine response analyses further uncovered clade-specific differences in pulmonary immune cell landscapes, the distribution of MPXV-positive cells, and the expression patterns of key inflammatory mediators at specific time points. Antiviral evaluation showed that tecovirimat and cidofovir were active against both clades, although a higher dose of cidofovir was required to achieve protection in the clade Ib infection model. Together, these findings establish a susceptible BALB/c mouse model for MPXV clade Ib and provide experimental evidence for clade-dependent differences in MPXV pathogenicity and antiviral treatment outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.